trending Market Intelligence /marketintelligence/en/news-insights/trending/MAr22mitf_Mgtr5jKjq8SA2 content esgSubNav
In This List

ContraVir Pharmaceuticals gets Nasdaq noncompliance notice

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


ContraVir Pharmaceuticals gets Nasdaq noncompliance notice

ContraVir Pharmaceuticals Inc. said it was evaluating its options after its stocks fell out of compliance with Nasdaq's minimum bid listing requirement of $1 per share.

The company has until Dec. 4 to regain compliance and may be eligible for a further extension.

The notice has no immediate effect on the company's listing on the stock market.